AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Oncternal Therapeutics In... (ONCT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.53

-0.16 (-23.63%)

At close: Dec 02, 2024, 9:00 PM

undefined% (undefined)

Bid	n/a
Market Cap	1.56M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-11.69
PE Ratio (ttm)	-0.05
Forward PE	n/a
Analyst	Hold

Ask	n/a
Volume	644,135
Avg. Volume (20D)	140,325
Open	0.70
Previous Close	0.69
Day's Range	0.53 - 0.70
52-Week Range	0.53 - 13.20
Beta	undefined

About ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is al...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 3, 2004

Employees 27

Stock Exchange NASDAQ

Ticker Symbol ONCT

Website https://www.oncternal.com

Analyst Forecast

According to 3 analyst ratings, the average rating for ONCT stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 1798.97% from the latest price.

Buy 33.33%

Hold 66.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago

-37.72%

Oncternal Therapeutics shares are trading lowers a... Unlock content with Pro Subscription

News

5 months ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executiv...

5 months ago · zacks.com

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.

8 months ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji ...

8 months ago · zacks.com

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $2.88. This compares to loss of $4 per share a year ago.

8 months ago · zacks.com

All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy

Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji...

10 months ago · zacks.com

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $3.11 per share versus the Zacks Consensus Estimate of a loss of $3.09. This compares to loss of $4 per share a year ago.

1 year ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - C...

1 year ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO C...

1 year ago · zacks.com

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.23 per share a year ago.

1 year ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Confer...

1 year ago · pennystocks.com

Penny Stocks To Buy? 10 Under $1 To Watch This Week

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

1 year ago · pennystocks.com

Penny Stocks To Buy? 7 Under $1 To Watch This Week

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?

1 year ago · zacks.com

Oncternal (ONCT) Down on Restructuring Plan to Extend Runway

Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.

1 year ago · investorplace.com

Why Is Oncternal Therapeutics (ONCT) Stock Down 62% Today?

Oncternal Therapeutics (NASDAQ: ONCT ) stock is falling hard on Tuesday after the company decided to end two clinical trials. Oncternal Therapeutics has announced that it's closing its Zilovertamab Ph...

1 year ago · seekingalpha.com

Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants James Breitmeyer - President and CEO Richard Vincent - CFO Salim Yazji - Chie...

1 year ago · seekingalpha.com

Oncternal Therapeutics: Making Progress And Still In Buy Territory

As ONCT's MCL Phase 2 study continues to mature, the data also continues to improve. In fact, the data now looks outstanding. Thus, I believe that the chances of success in the newly initiated Phase ...